Guizhou Yibai Pharmaceutical Co., Ltd. is an enterprise integrating the research, development, production and sales of new drugs. The company was founded on June 12, 1995, completed the shareholding reform in November 2000, and was successfully listed on the Shanghai Stock Exchange in March 2004 (stock code 600594).

The company covers an area of ​​134,398 square meters and has a production plant that complies with the National Drug Production Quality Management Specifications (GMP for short). Currently, it has 3 production bases within the province and 4 production bases outside the province. There are 49 product specifications, including small injections, freeze-dried powder injections, large infusions, and 9 injection production lines.

As of December 2012, the company's industrial output value was nearly 3 billion yuan and sales revenue was nearly 2.8 billion yuan (group merged data). In 2012, Guizhou Province paid 386 million yuan in taxes. Since its establishment, the company has paid more than 2.3 billion yuan in taxes to the state. January-June 2013.

During the development process, the company has been focusing on improving corporate governance and continuously improving its corporate governance level.

The company currently has more than 4,000 employees. Based on the concept of "cultivating people for a hundred years", the company has always attached great importance to employees' training and carried out various forms of training for employees. Through learning and training, it has effectively improved the work enthusiasm of all employees and improved the overall quality of employees. The company's senior management personnel were sent to Tsinghua University, China Europe International Business School, Guoyan Stanford, Changjiang Management College, Shanghai Jiaotong University and other institutions for management study, and held general manager training classes within the company, hired experts to attend classes, and selected company managers and some employees to participate, aiming to improve the comprehensive quality of management personnel.

The company also sends professional and technical personnel to relevant pharmacy colleges for professional training, focusing on improving the company's technical strength and cultivating innovative spirit; adhering to the worker training system, continuously strengthening the improvement of workers' cultural quality, cultivation and technical skills, and the entire company's employees strictly conduct corresponding training at more than 300 school hours per year.

The company's current main products include Keke family series, Eddie injection, Ginkgo Damo injection, Loplatin for injection, compound Banban capsules, Liqihuxue Drip Pills, Qianlihuangditong Granules and many other advantageous varieties. Among these products that have formed a series of advantages in the enterprise, the compound Chinese medicine injections Eddie Injection and Compound Banju Capsule are new biphasic anti-tumor drugs, among which the research of Eddie Injection has reached the genetic level; the fourth-generation Ginkgo Damo Injection, Ginkgo Damo Injection is an effective treatment for cardiovascular, cerebrovascular and peripheral circulation disorders, and its release has brought good news to the majority of patients with cardiovascular and cerebrovascular diseases; Loplatin for injection is a first-class new drug in the country, and the third-generation platinum anti-tumor drug, which is less toxic and less drug resistance than other platinum. Liqi Huoxue Drops are the original Miao medicine, a first-line medicine for the treatment of cardiovascular diseases, and have great market potential.

The company has established a good marketing network in major cities across the country and equipped with a well-trained sales team to achieve quality tracking services for the entire process from products to patient services.

In order to promote the optimization of the pharmaceutical industry structure and improve product concentration, the company has successively acquired production pharmaceutical companies such as Guilin Lijiang Pharmaceutical, Yunnan Nanzhao Pharmaceutical, Guizhou Minzu Pharmaceutical, Hainan Changan Pharmaceutical and other production pharmaceutical companies in the past few years. The varieties of these companies have been sold well in the market and have very broad market prospects. In 2012, Yibai once again accelerated its integration and merger, acquired 80% of the shares of Beijing Aide Pharmaceutical Co., Ltd., and integrated the development, production and sales of genetically engineered drugs into Yibai's pharmaceutical and health industry chain in one fell swoop.